Drug Interaction Report

GENERALLY AVOID: Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fruquintinib, which is primarily metabolized by the isoenzyme. Concomitant use with efavirenz, a moderate CYP450 3A4 inducer, decreased fruquintinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 4% and 32%, respectively. Reduced efficacy of fruquintinib may occur.

MANAGEMENT: Coadministration of fruquintinib with moderate CYP450 3A4 inducers should generally be avoided. The potential for diminished pharmacologic effects of fruquintinib should be considered during coadministration with moderate CYP450 3A4 inducers. However, if concomitant use is required, the manufacturer advises that fruquintinib may be continued at the recommended dosage.